News|Articles|November 17, 2026

Lung Cancer Survival Rate Climbs to 31%, Although Screening Gaps Persist

Fact checked by: Russ Conroy

The American Lung Association is urging Congress to pass the Clinical Trial Modernization Act, which may help advance research and care.

The 5-year lung cancer survival rate in the US has risen to 31.0%—up from 18.1% when the American Lung Association (ALA) issued its first report in 2018—yet lung cancer remains the leading cause of cancer death nationally, and only 24.4% of eligible individuals are being screened, according to the ALA’s ninth annual “State of Lung Cancer” report.¹ Released alongside a call for Congress to pass the bipartisan Clinical Trial Modernization Act, the report estimates that 229,410 people will be diagnosed with lung cancer in the US this year.²

What did the report show on survival, screening, and early diagnosis?

The national 5-year survival rate of 31.0% represents a 24% increase over the past 5 years, which the ALA attributed to advances in research, treatment, and earlier detection. Survival ranged from a high of 40.9% in Massachusetts to a low of 23.8% in Alabama. However, lung cancer screening with annual low-dose CT—which can reduce the lung cancer death rate by up to 20%—remains underused, with only 24.4% of eligible high-risk individuals screened nationally, ranging from 38.7% in Massachusetts to 13.5% in South Dakota. Just 29.3% of cases are diagnosed at an early stage, when the 5-year survival rate is 65.0%, compared with 12.0% when caught late.

“Lung cancer is a devastating disease, but the positive trends detailed in our latest report offer hope,” said Harold Wimmer, president and chief executive officer of the ALA, in a news release.2 “Awareness is still low and challenges remain. We must continue to drive progress on lung cancer screening, comprehensive biomarker testing, clinical trials and effective treatments to help people live longer, fuller lives after a lung cancer diagnosis.”

What disparities did the report highlight?

The report showed that survival varied significantly by race and ethnicity: 35.4% among Asian and Pacific Islander individuals, 30.8% among both White and Latino individuals, 26.1% among Black individuals, and 18.2% among Indigenous Peoples. Compared with White individuals, Black individuals were 13% less likely to be diagnosed early, 17% less likely to receive surgical treatment, and 15% less likely to survive 5 years, while Indigenous Peoples were 27% less likely to receive surgery and 41% less likely to survive 5 years.

Why does lung cancer among those without smoking history matter?

Although smoking remains the leading cause of lung cancer—accounting for 80% to 90% of cases—the report emphasized that radon, air pollution, and secondhand smoke are also established risk factors, a point echoed by Chinmay Jani, MD, a medical oncologist at Sylvester Comprehensive Cancer Center of the University of Miami Miller School of Medicine, who has researched non-tobacco contributors to lung cancer.

“Smoking is not equal to lung cancer. That’s what, historically, it used to be, and that’s what people still believe, and we need to change that paradigm,” Jani said in an interview with CancerNetwork®, citing research he and colleagues published in eClinicalMedicine showing that non-tobacco-associated lung cancer accounts for approximately 35% to 40% of cases globally, with a higher proportion among women.3 Jani added that this reality should reshape how clinicians approach diagnosis and stigma. “Trying to stigmatize and making them feel guilty that they were smoking and that’s what led to this cancer is not an appropriate way to start someone’s treatment,” he said.

How do early detection and biomarker testing fit in?

Both the report and Jani underscored early detection as central to improving outcomes. “The earlier the diagnosis happens at the earlier stage, the cure rates are also significantly higher,” Jani said, noting that detection before symptoms develop can spare patients from needing systemic therapy. The report also examined insurance coverage of comprehensive biomarker testing, which helps match patients to targeted therapies and immunotherapy; 19 states require coverage of comprehensive biomarker testing, 7 require some coverage, and 25 states plus Washington, DC, do not require any coverage. Jani framed molecular profiling as essential, particularly as younger patients more often harbor actionable driver mutations.

“The most important factor, even for the younger patient, is that comprehensive genomic testing and comprehensive next-generation sequencing needs to be done,” Jani said.

What is the policy call to action?

The ALA is urging Congress to pass the bipartisan Clinical Trial Modernization Act (H.R. 3521/S. 4440), which it says would reduce barriers to trial participation and make clinical trials more accessible, including for people with lung cancer. The organization noted that all lung cancer screening and treatment advances recommended today were first studied in clinical trials, and that expanding access to trials and to appropriate treatment is a key component of continuing to improve lung cancer outcomes.

References

  1. Lung cancer key findings. American Lung Association. Updated November 10, 2026. Accessed November 17, 2026. https://tinyurl.com/2jmfh4me
  2. New report: despite gains in survivorship and screening, lung cancer remains the leading cause of cancer death in the U.S. News release. American Lung Association. November 17, 2026. Accessed November 17, 2026. https://tinyurl.com/yj42mu3h
  3. Jani CT, Kareff SA, Morgenstern-Kaplan D, et al. Evolving trends in lung cancer risk factors in the ten most populous countries: an analysis of data from the 2019 Global Burden of Disease Study. EClinicalMedicine. 2025;79:103033. doi:10.1016/j.eclinm.2024.103033

Related to this article